The present invention relates to (1, -1 λ * 6*- thiapyran -4- base of 1- dioxo - hexahydro - { (S-3- [1- (6- methoxyl group -5- methvl-pyridinium -3- base) -2,3- dihydro -1H- pyrido [3,4-b] [1,4] oxazines -7- base oxygroup] - pyrrolidin-1-yl - ketone anhydrous crystalline forms； Pharmaceutical composition and combination product comprising these crystal forms, further relate to the method using these crystal forms, the method including using pharmaceutical composition and combination product to treat disease.本發明涉及(1,1-二氧代-六氫-1λ＊6＊-噻喃-4-基-{(S-3-[1-(6-甲氧基-5-甲基-吡啶-3-基)-2,3-二氫-1H-吡啶并[3,4-b][1,4]噁嗪-7-基氧基]-吡咯烷-1-基}-甲酮的無水結晶形式；包含這些結晶形式的藥物組合物和組合産品，還涉及使用這些結晶形式的方法，包括使用藥物組合物和組合産品治療疾病的方法。
